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Adeno-associated virus (AAV) has provided the gene therapy
ﬁeld with the most powerful in vivo gene delivery vector to
realize safe, efﬁcacious, and sustainable therapeutic gene
expression. Because many clinically relevant properties of
AAV-based vectors are governed by the capsid, much research
effort has been devoted to the development of AAV capsids for
desired features. Here, we combine AAV capsid discovery from
nature and rational engineering to report an AAV9 capsid
variant, designated as AAV9.HR, which retains AAV9’s capa-
bility to traverse the blood-brain barrier and transduce neu-
rons. This variant shows reduced transduction in peripheral
tissues when delivered through intravascular (IV) injection
into neonatal mice. Therefore, when IV AAV delivery is used
to treat CNS diseases, AAV9.HR has the advantage of
mitigating potential off-target effects in peripheral tissues
compared to AAV9. We also demonstrate that AAV9.HR is
suitable for peripheral tissue-detargeted CNS-directed gene
therapy in a mouse model of a fatal pediatric leukodystrophy.
In light of recent success with proﬁling diversiﬁed natural
AAV capsid repertoires and the understanding of AAV capsid
sequence-structure-function relationship, such a combinatory
approach to AAV capsid development is expected to further
improve vector targeting and expand the vector toolbox for
therapeutic gene delivery.
INTRODUCTION
Adeno-associated virus (AAV) is a small, non-pathogenic virus found
in many mammals, including humans. The simple architecture of
AAV comprises an icosahedral capsid of 26 nm in diameter and a
single-stranded DNA genome of 4.7 kb.1 Due largely to its superb
in vivo tissue tropism for both dividing and non-dividing cells, re-
combinant AAV (rAAV) has been developed as a gene delivery vec-
tor, drawing considerable interest particularly in the gene therapy
ﬁeld. rAAV development has been greatly facilitated by the discovery
of numerous AAV capsid serotypes and variants from both human
and nonhuman primate (NHP) tissues, which collectively provide a
toolbox for targeting a variety of tissue and cell types.2 These naturally
existing capsids also serve as lead templates for rational capsid engi-
neering guided by structure-function analysis, such as surface decora-
tion with speciﬁc receptor ligands3 or alteration of speciﬁc residues
involved in cellular interaction.4 In addition, directed evolution
from random DNA shufﬂing or mutagenesis libraries also yielded
capsids that have clinically relevant features.5
Among all the AAV serotypes and variants tested so far, AAV9 has
gained popularity in gene therapy applications due to its high tropism
in tissues, such as liver, heart, and skeletal muscle following intravas-
cular (IV) delivery.6 In addition, its capability of traversing the blood-
brain barrier (BBB) and transducing cells residing in the CNS opens
new avenues for CNS gene therapy.7,8 For example, IV delivery of
rAAV9 expressing the human ASPA gene proved to be efﬁcacious
in rescuing most disease phenotypes in a mouse model of ASPA
deﬁciency (Canavan disease), a white matter neurodegenerative dis-
order.9,10 Recently, a clinical trial for spinal muscular atrophy by
IV-delivered rAAV9 showed early promising results.11 In parallel
with pursuing stronger transduction in target tissues following IV de-
livery of rAAV, de-targeting speciﬁc tissues is often a desired feature
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to diminish potential off-target toxicity.12 Several approaches have
been taken in this regard. First, a tissue-speciﬁc promoter can be uti-
lized to restrict gene expression.13 Second, microRNA (miRNA)
binding sites that are recognized by endogenous tissue-speciﬁc
miRNAs can be engineered in the transgene 30 UTRs, which will
silence transgene expression in that tissue.14 Third, a vector library
obtained by capsid engineering can be screened for a desired trans-
duction proﬁle.15 The most signiﬁcant limitation to systemic rAAV
gene therapy in numerous clinical trials has been the effector T cell
response to the input rAAV capsid proteins.16 Thus, only those de-
targeting strategies that decrease exposure of the liver to capsids,
rather than those that limit transgene expression alone, are likely to
result in substantial improvements in the efﬁcacy and safety proﬁle.
Research on the AAV capsid structural biology has provided valuable
knowledge in understanding its characteristics and guiding vector
development for gene therapy.17 The AAV capsid consists of 60
copies of viral protein (VP) subunits, with VP1, VP2, and VP3 at
1:1:10 ratio. The capsid structure of a handful of wild-type (WT)
AAV serotypes has been determined by cryo-electron microscopy
(cryo-EM) followed by three-dimensional image reconstruction
and/or X-ray crystallography.17 VP3 monomers from all examined
serotypes share a conserved b-barrel core consisting of eight antipar-
allel b sheets. The large loops connecting the b strands contain nine
variable regions (VR-I to -IX) that are accessible from the solvent
side for interactions with cellular receptors and antibodies. The
VRs are highly diverged between serotypes and likely determine
capsid characteristics, such as tropism and immunogenicity. One
noticeable feature of all known AAV capsid structures is the protru-
sions surrounding the icosahedral three-fold axes of symmetry, where
most VRs are located. Therefore, the three-fold protrusions play an
important role in shaping the unique properties of each variant
capsid.
For AAV9, the primary receptor is cell surface glycans with terminal
b-galactose.18,19 The galactose binding domain on AAV9 capsid has
been mapped to a pocket at the base of the three-fold protrusions
formed by N470, D271, N272, Y446, and W503.20 The neighboring
512NGR514 tripeptide motif has been implicated in cell entry in vivo
through interaction with integrin.21 In addition, the 37/67-kilodalton
laminin receptor (LamR) expression level plays a role in AAV9-based
vector transduction in vitro, and residues 489–545 and 591–621 of
AAV9 VP are equivalent to AAV8 VP residues that interact with
LamR in a yeast two-hybrid binding assay.22 A distinctive feature of
AAV9 compared with other serotypes, such as AAV1, is its delayed
blood clearance, which is attributable to residues 456–568 and is sug-
gested to contribute to AAV9’s robust cardiac transduction in mice.23
When mapped to the AAV9 capsid structure,24 most residues
involved in receptor binding and blood clearance are located at or
near the three-fold protrusions, highlighting their important role in
mediating cellular interactions and determining capsid properties.
Here, taking an approach combining AAV capsid discovery from na-
ture and rational design, we report the AAV9.HR capsid that differs
from AAV9 by two amino acid residues that are located at the
three-fold protrusions. Following IV delivery, this capsid is able to
transduce neurons in broad brain regions with a peripheral tissue
de-targeting property and is suitable for CNS gene therapy.
RESULTS
Discovery of AAV Capsid Variants
In an attempt to discover naturally existing AAV capsid sequences
from NHP, we extracted total DNA and RNA from chimpanzee tis-
sues, including brain, liver, lung, and spleen. We found several previ-
ously reported AAV serotype capsid sequences, including AAV3B,
4, 5, and 9. In addition, we discovered 121 variants with capsid se-
quences similar to AAV1, 3B, 4, 5, 6, and 9 (Figure S1). Forty-seven
of these sequences were variants of AAV9 differing from the WT
AAV9 capsid sequence by no more than nine amino acid residues
(Table S1). The AAV9 capsid shows broad and strong tissue tropism
in vivo and is able to traverse the BBB following systemic delivery.
Therefore, we decided to focus on the characterization of one of these
AAV9 variants in this study, hypothesizing that a minimal number of
capsid changes may alter the tropism properties of AAV9, thus allow-
ing for residue function analysis and generating useful vectors for
in vivo gene delivery.
The CLv-D8 Capsid Variant Transduced Liver Much Less
Efficiently Than AAV9
Among the AAV9 variants, we noticed the conservation of four res-
idue changes amongmultiple isolates, namely Y445H, H527Y, R533S,
and I647T (AAV9 residue type in front; AAV9 VP1 numbering;
Table S1). We modeled these four residue changes onto the AAV9
capsid crystal structure.24 As shown in Figure 1A, three of the four
residues cluster near the three-fold axis. The 445H resides at the inter-
face of two three-fold-related VP monomers, and 647T is located in
the conserved bH strand and buried within the eight-stranded b-bar-
rel motif. These two residues are not visible from the capsid surface
view (Figure 1B). The 527Y and 533S residues are located at the pro-
trusions surrounding the three-fold axis (Figure 1B), which have been
shown to have an impact on receptor binding, including galactose and
LamR, and blood clearance of rAAV vectors.20,22,23 Therefore, we
decided to further examine the CLv-D8 (clone D8 from chimpanzee
liver) variant that harbors all four residue changes along with the
527Y and 533S changes.
To characterize the in vivo tissue transduction proﬁle of AAV.CLv-D8
compared with AAV9 (AAV9wt hereafter), we packaged a single-
stranded recombinant AAV genome expressing ﬁreﬂy luciferase
(Fluc) into both capsids and compared in vivo transduction following
IV injection of 1  1011 genome copies (GCs) into adult mice.
Whereas rAAV9wt-Fluc yielded strong Fluc expression in the liver
as previously reported,6 rAAV.CLv-D8-Fluc-treated mice displayed
reduced bioluminescence from the liver (Figure 1C). Delivery of the
same amount of the vector genomes by intramuscular (IM) injection
at the left tibialis anterior muscle (LTA) also showed reduced liver
transduction with the rAAV.CLv-D8-Fluc vector, whereas the signal
from LTA was comparable between the two vectors (Figure 1C).
www.moleculartherapy.org
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The AAV9.HR Capsid Mutant Recapitulates the Liver
De-targeting Property of CLv-D8
To examine the contributions of the surface-exposed residues 527Y and
533S to the reduced liver transduction proﬁle of AAV.CLv-D8 relative
to AAV9wt, we made AAV9 capsid “single mutants,” carrying either
residue changes, and “double mutants,” carrying both residue changes.
By in vivo imaging, the single-mutant vector rAAV9.R533S-Fluc
showed reduced liver transduction compared with rAAV9wt-Fluc
following IV or IM injection of the same dose (Figure 2A). Notably,
the double-mutant vector rAAV9.HR-Fluc, containing the H527Y
and R533S mutations, showed similarly reduced liver transduction as
the rAAV.CLv-D8-Fluc vector (Figure 2A). Single changes at the 445
and 647 positions, as well as double-mutant combinations containing
them, did not show reduced liver expression and were not studied
further (data not shown).
After in vivo imaging, we sacriﬁced the mice and harvested liver and
LTA muscle to quantitatively measure rAAV genome abundance by
qPCR and transduction efﬁciency by luciferase activity in tissue
lysates (Figure 2B). Both assays corroborated the results of in vivo
imaging. Speciﬁcally, following IV injection of the rAAV9.HR vec-
tor, the rAAV genome copy (GC) number in liver was only 0.5% of
rAAV9wt vector levels, suggesting that the AAV9.HR capsid mutant
had signiﬁcantly reduced tropism in this organ compared to WT.
Correspondingly, the luciferase activity in the liver was reduced to
4.0% of WT. The decreases were comparable to observations with
the rAAV.CLv-D8 vector (Figure 2B). In contrast, there was no sig-
niﬁcant difference among the vectors tested in LTA muscle trans-
duction (Figure 2B, top panels). Following IM injection, similar liver
de-targeting proﬁle was observed with the rAAV9.HR vector, 8% of
GC number and 0.5% of luciferase activity relative toWT (Figure 2B,
bottom panels). The genome copies and transduction level in LTA
muscle (the injected muscle) again did not show signiﬁcant differ-
ence among the vectors (Figure 2B, bottom panels). For the sin-
gle-mutant vectors, only rAAV9.R533S showed signiﬁcant liver
de-targeting following IM injection but did not fully recapitulate
the characteristics of the rAAV.CLv-D8 vector following IV injec-
tion as the rAAV9.HR vector did (Figures 1C and 2). Therefore,
we conclude that both the 527Y and 533S residues in the CLv-D8
capsid variant synergistically contribute to its liver de-targeting
property in mice.
Several reports suggested that the blood clearance kinetics of rAAV
have an impact on peripheral tissue tropism following IV delivery.23,25
Moreover, residues 456–568 of AAV9 VP have been shown to deter-
mine its delayed blood clearance kinetics.23 Both residues 527Y and
533S are located within this region. However, we did not observe
any signiﬁcant difference in blood clearance among rAAV9wt,
rAAV9.H527Y, rAAV9.R533S, rAAV9.HR, and rAAV.CLv-D8 (Fig-
ure S2). Although rAAV9.HR and rAAV.CLv-D8 performed similarly
in the gene delivery, transduction, and blood clearance assays, the ti-
ters of rAAV.CLv-D8 preparations were consistently lower than
rAAV9.HR preparations when the same genome was packaged (Fig-
ure S3), indicating a potential advantage of the engineered AAV9.HR
Figure 1. Capsid Structure Characteristics and In Vivo Transduction Profile
of rAAV.CLv-D8
(A) Side view of a trimer comprising three copies of AAV9 VP protein.24 The four
residues in CLv-D8 that differ from AAV9 are modeled in spheres and labeled with
color. White spheres are residues involved in galactose binding.20 (B) Surfacemodel
of the trimer shown in (A) presented in top view (left) or side view (right) is shown. The
533S and 527Y residues found in CLv-D8 are labeled when visible. Residues in dark
green are involved in LamR binding.22 Residues in lime green have impact on blood
clearance kinetics.23 Residues in white are involved in galactose binding.20 (C)
In vivo imaging of luminescence at four weeks after intravascular (IV) or intramus-
cular (IM) injection of 1.0E+11 genome copies (GCs) of luciferase-expressing rAAV
packaged into the wild-type AAV9 capsid (rAAV9wt; n = 3) or the CLv-D8 capsid
(rAAV.CLv-D8; n = 3) is shown. In the IM delivery, rAAVs were injected into the left
tibialis anterior muscle. Naive mice that did not receive any rAAV serve as back-
ground controls (n = 2). Luminescence intensity is presented on a color-coded scale
shown on the right in the unit of photons/s/cm2/sr.
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capsid over the naturally existing CLv-D8 isolate. Therefore, the trans-
duction pattern of AAV9.HR was further characterized.
scAAV9.HR-EGFP Vector Displayed Reduced Transduction of
Both Peripheral and CNS Tissues by High-Dose IV Injection into
Adult Mice
The ability to cross the BBB and to transduce the cells within CNS
following high-dose IV delivery is an attractive feature of rAAV9
that holds great promise for CNS gene therapy. However, this CNS-
targeted treatment regimen will highly transduce major peripheral or-
gans, such as the liver, which may cause detrimental off-target effects.
To test whether rAAV9.HR can also reach the CNS while de-targeted
from peripheral organs, we treated young adult mice with high-dose
(4.0E+12 GC) self-complementary (sc)AAV9wt or scAAV9.HR car-
rying the same EGFP-expressing genome by IV delivery and compared
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Figure 2. rAAV9.HR Showed Reduced Liver Tropism
Relative to rAAV9wt following IV or IMDelivery inMice
(A) In vivo imaging of luminescence at four weeks after IV or
IM injection of 1.0E+11 GC of luciferase-expressing rAAV
packaged into WT AAV9 or each of three AAV9 capsid
mutants, namely H527Y (rAAV9.H527Y; n = 3), R533S
(rAAV9.R533S; n = 3), or H527Y/R533S (rAAV9.HR; n = 3).
Luminescence intensity is presented by a color-coded scale
shown on the right in the unit of photons/s/cm2/sr. The
rAAV9wt-treated mice shown in Figure 1 are included for
comparison. (B) Bar graphs show molecular characteriza-
tion of genome abundance and transduction of different
rAAV vectors in the liver and left tibialis anterior (LTA) muscle
at four weeks after IV (top panels) or IM (bottom panels)
delivery (n = 3). rAAV genome copy data (left panels) are
presented in genome copies per diploid genome (GC/
diploid genome). Luciferase activity data are presented in
relative light units per 100 mg of total protein (RLU/100 mg
protein). Values shown above the rAAV9.HR bars denote
the percentage relative to the rAAV9wt group (defined as
100%). All values are presented as mean and SD. *p < 0.05
and **p < 0.01 by one-way ANOVA; ns, not significant by
one-way ANOVA; #p < 0.05 and ##p < 0.01 by Tukey’s
multiple comparisons test against the rAAV9wt group.
EGFP expression in tissue sections. As shown in
Figures 3A and 3B, EGFP ﬂuorescence in heart
and tibialis anterior (TA) was greatly reduced
with scAAV9.HR compared to scAAV9wt,
whereas there was no statistically signiﬁcant differ-
ence in the liver. In the adult CNS, scAAV9wt-
EGFP yielded widespread transduction in the
brain and in the gray matter of the spinal cord as
previously described,7,8 whereas the scAAV9.HR-
EGFP vector led to much weaker transduction
(Figure 3C). By performing immunoﬂuorescence
co-staining, we observed that transduction
occurred in the hippocampal neurons (Figure 3D)
in addition to vasculature (Figure S4), conﬁrming
the ability of high-dose rAAV9 to traverse adult
BBB. Neuronal transduction was noticeably reduced with the
scAAV9.HR-EGFP vector at the same dose (Figure 3D).
Overall, when compared with the parental AAV9 capsid, the
AAV9.HR double mutant capsid shows reduced in vivo transduction
in a subset of peripheral tissues and CNS following high-dose IV de-
livery of sc vectors into young adult mice.
IV Delivery of scAAV9.HR-EGFP to Neonatal Mice Resulted in
Widespread Neuronal Transduction in the CNS with Peripheral
Tissue De-targeting Compared with scAAV9wt-EGFP
rAAV9 vectors transduced neurons more efﬁciently following IV de-
livery into neonatal mice than into adult mice.7 Therefore, we next in-
jected 4.0E+11 GC of scAAV9wt-EGFP or scAAV9.HR-EGFP into
postnatal day 1 (P1) pups and compared transduction proﬁle of the
www.moleculartherapy.org
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two vectors in both peripheral tissues and CNS. Consistent with the
results in young adult mice, we observed comparable EGFP expres-
sion in the liver but signiﬁcantly reduced EGFP expression in the
heart and TA muscle with scAAV9.HR (Figures 4A and 4B). One
should note that the sparse EGFP-expressing cells in the liver was
likely attributable to the dilution of rAAV genomes along with rapid
hepatocyte division after birth.26 In both brain and spinal cord,
scAAV9.HR-EGFP showed generally comparable transduction with
scAAV9wt-EGFP regarding spread and efﬁciency, except for the hip-
pocampus in the brain and the dorsal portion of the spinal cord,
where transduction by scAAV9.HR-EGFP was weaker (Figures 4C
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Figure 3. Comparison of scAAV9wt and scAAV9.HR
Transduction Profiles following IV Delivery of High
Dose (4.0E+12 GC) into Young Adult Mice (Six
Weeks Old)
(A) Representative fluorescence images showing
native EGFP fluorescence in tissue sections of liver, heart,
and TA muscle at three weeks after treatment with self-
complementary (sc) EGFP-expressing vectors pack-
aged into AAV9 capsid (scAAV9wt) or AAV9.HR capsid
(scAAV9.HR). The scale bar represents 500 mm. (B)
Quantification of EGFP signal in tissue sections is shown.
EGFP signal is quantified by percentage of EGFP-positive
pixels (% EGFP positive, top panel) or the average inte-
grated intensity calculated as the ratio of total intensity
over area (intensity/area, bottom panel). n = 3 for each
group. Data are presented as mean and SD. **p < 0.01
and ns, not significant by Student’s t test. (C) Represen-
tative immunofluorescence images show anti-EGFP
signal in brain and spinal cord (lumbar region) sections.
Untreated samples processed in the same manner as the
treated samples serve as fluorescence background
control. (D) Representative confocal immunofluorescence
images show anti-EGFP signal (green), neurons (red,
labeled as NeuN-positive), and merged signal (yellow) in
the hippocampus (squared region in C). The scale bar
represents 200 mm.
and 4D). Immunoﬂuorescence labeling and
confocal microscopy conﬁrmed that both vec-
tors resulted in neuronal transduction in
various brain regions, including hippocampus,
thalamus, and cortex (Figure 5). In addition,
some cells transduced by either scAAV9wt or
scAAV9.HR appear to be astrocytes based on
morphology, consistent with previous reports
that AAV9 has high tropism for astrocytes.7,8
rAAV9.HR-Mediated ASPA Gene
Replacement Therapy Rescued Canavan
Disease Phenotypes in a Mouse Model of
the Disease
Encouraged by the ﬁnding that, following IV
delivery into neonatal mice, the AAV9.HR
capsid mutant is able to achieve comparable
transduction to AAV9wt in most CNS compartments examined but
reduced transduction in the heart and TA muscle, we next asked
whether a therapeutic rAAV9.HR vector for treating a CNS disease
is efﬁcacious. To this end, we constructed a single-stranded rAAV
genome expressing an optimized human ASPA gene (see Materials
and Methods) and packaged into the AAV9wt or AAV9.HR capsid
for gene replacement therapy in a mouse model of Canavan disease
(CD). We injected 4.0E+11 GC of each vector into P1 CD mice and
evaluated their therapeutic efﬁcacy by a series of established measure-
ments.9,27 First, the saline-treated control mice showed signs of brain
edema as revealed by T2-weighted MRI; both vectors completely
Molecular Therapy: Methods & Clinical Development
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corrected this phenotype (Figure 6A). Second, both vectors
completely cleared brain N-acetylaspartic acid (NAA) accumulation
due to ASPA deﬁciency seen in the saline-treated control CD mice
as determined by magnetic resonance spectroscopy (MRS) (Fig-
ure 6B). Third, both vectors rescued the early lethality seen in the
control CD mice and extended lifespan up to nine months, which
was the duration of this study (Figure 6C). Fourth, treatment with
rAAV9.HR-ASPA corrected the body weight loss observed in control
CDmice during their short lifespan (Figure 7A) and over an extended
period of time (Figure S5A). Fifth, treatment with rAAV9.HR-ASPA
also restored the motor function toWT level, as revealed by three mo-
tor function tests, namely the rotarod test, the inverted screen test,
and the balance beam test (Figure 7B). The CD mice receiving
rAAV9wt-ASPA outperformed the WT mice in the rotarod test, re-
sulting in a super-mouse phenotype as we previously reported.10
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Figure 4. Comparison of scAAV9wt and scAAV9.HR
Transduction Profiles following IV Delivery of High
Dose (4.0E+11 GC) into Newborn Mice (P1)
(A) Representative fluorescence images showing native
EGFP fluorescence in tissue sections of liver, heart,
and TA muscle at three weeks after treatment with
EGFP-expressing vectors packaged into AAV9 capsid
(scAAV9wt) or AAV9.HR capsid (scAAV9.HR). The scale
bar represents 500 mm. (B) Quantification of EGFP signal
in tissue sections is shown. EGFP signal is quantified by
the percentage of EGFP-positive pixels (% EGFP positive,
top panel) or the average integrated intensity calculated
as the ratio of total intensity over area (intensity/area,
bottom panel). n = 4 for each group. **p < 0.01 and ns, not
significant by Student’s t test. (C) Representative immu-
nofluorescence images show EGFP signal in the brain and
spinal cord (lumbar region) sections. Untreated samples
processed in the same manner as the treated samples
serve as fluorescence background control. Cerebral
cortex (ctx), hippocampus (hpc), thalamus (thl), ventral
horn of spinal cord (sc-v), and dorsal horn of spinal cord
(sc-d) are highlighted and subjected to signal quantifica-
tion. (D) Quantification of the immunofluorescence signal
of the CNS regions shown in (C) is shown (n = 4). **p <
0.01 and ns, not significant by Student’s t test. Data are
presented as mean and SD.
Importantly, the motor function improvement
proved to be sustainable up to 180 days, the
last time point when such tests were performed
(Figure S5B). These results demonstrate that the
AAV9.HR capsid mutant is suitable for vector
development to target CNS diseases.
In a subset of treated CD mice, we quantiﬁed
gene delivery efﬁcacy of both ASPA vectors in
various tissues. Consistent with the data of P1
injection with EGFP vectors (Figures 4C and
4D), the rAAV9.HR-ASPA and rAAV9wt-
ASPA resulted in comparable genome delivery
and expression in the cerebral cortex and thalamus, whereas
rAAV9wt-ASPA was superior in hippocampus by both measure-
ments (Figure 8). We also found de-targeting of rAAV9.HR-ASPA
in all peripheral tissues examined, including liver, heart, and TAmus-
cle (Figure 8). This is in contrast to the performance of the
scAAV9.HR-EGFP vector that showed de-targeting in the heart
and TA muscle, but not liver (Figures 4A and 4B).
DISCUSSION
The AAV9.HR capsid described in this study will be useful in
various gene therapy applications requiring de-targeting in speciﬁc
tissues. First, following IM delivery, rAAV9.HR has tropism and
transduction in the injected muscle as high as rAAV9, but liver
tropism and transduction is diminished (Figure 2). This makes
AAV9.HR an attractive capsid for muscle-directed gene delivery
www.moleculartherapy.org
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Figure 5. scAAV9.HR and scAAV9wt Transduced
Neurons in Various Brain Regions following IV
Delivery of 4.0E+11 GC into Newborn Mice (P1)
Representative confocal immunofluorescence images
showing anti-EGFP signal (green), neurons (red, labeled
as NeuN-positive), and merged signal (yellow) in the hip-
pocampus (A), thalamus (B), and cortex (C). The scale bar
represents 200 mm.
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when unwanted liver transduction may cause toxicity. In addition,
muscle-speciﬁc promoter and a miRNA de-targeting strategy can
be utilized along with the AAV9.HR capsid to further restrict gene
expression in the muscle. Second, following IV delivery into neo-
nates, AAV9.HR vectors packaging either a sc genome (Figures
4C and 4D) or a single-stranded (ss) genome (Figure 8) yielded
widespread brain transduction as efﬁciently as AAV9wt except for
hippocampus, but transduction in peripheral tissues is greatly
reduced. This feature of AAV9.HR will reduce the risk of off-target
toxicity in peripheral tissues when the vector is applied for CNS gene
therapy. We observed peripheral tissue de-targeting in the heart and
skeletal muscle with the scAAV9.HR-EGFP vector; in contrast, de-
targeting occurred in the liver, heart, and skeletal muscle with the ss
rAAV.HR-ASPA vector. We postulate that the difference in liver de-
targeting between the two vectors may be due to the genome conﬁg-
uration. Consistent with this notion, the ss rAAV9.HR-Fluc vector
also showed liver de-targeting compared with rAAV9wt-Fluc
following IV delivery (Figure 2).
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Figure 6. IV Delivery of rAAV9.HR-ASPA at P1 to CD
Mice Corrected Brain Pathology and Extended
Survival as Efficiently as rAAV9wt-ASPA
(A) Coronal series of T2-weighted MRI brain images ob-
tained from an untreated wild-type mouse (WT, P42) and
Canavan disease (CD) mice treated with 0.9% NaCl (NaCl,
P27), rAAV9wt-ASPA (rAAV9wt, P42), or rAAV9.HR-ASPA
(rAAV9.HR, P42). Note that treatment with either rAAV9wt
or rAAV9.HR in CD mice completely normalized the hy-
perintensity seen in the NaCl-treated CD mouse. (B) Bar
graph shows NAA levels normalized to creatine levels
(tNAA/tCr; determined by MRS) in the brains of CD mice
treated as described in (A) (n = 3). **p < 0.01 and ns, not
significant by Tukey’s multiple comparisons test following
one-way ANOVA. Dashed line indicates WT level. Data are
presented as mean and SD. (C) Kaplan-Meier survival
curves show the percentage of survived mice over time
course, including CD mice that were left untreated (red,
n = 12), treated with rAAV9wt-ASPA (gray, n = 12), or
treated with rAAV9.HR-ASPA (purple, n = 13).
With the exception of the change at amino acid
position 647, the CLv-D8 amino acid differ-
ences to WT AAV9 are located on the protru-
sions that surround the icosahedral 3-fold
axis. This capsid region has been implicated
as a determinant of receptor binding and
cellular transduction for numerous AAVs,
including AAV9.18–20,22,23 The surface location
of H527Y and R533S and their effect on tissue
tropism highlights their potential role in similar
functions on the AAV capsid. The mechanism
underlying the tissue de-targeting property
conferred by the H527Y and R533S mutations
following a systemic route remains to be stud-
ied. Nevertheless, the notion that AAV9.HR is
a viable capsid for CNS gene therapy is fortiﬁed
by the successful gene replacement therapy in a mouse model of
Canavan disease, a fatal neurological disease affecting broad brain
regions (Figures 6 and 7).
Following IV delivery, the two-residue change in AAV9.HR
compared with AAV9, i.e., H527Y+R533S, severely impairs brain
transduction in young adult mice, but not so much in neonatal
mice (Figures 3 and 4). We also notice that IV rAAV9wt and
rAAV9.HR vectors transduce massive structures resembling blood
vessels in the young adult brain but much less so in the neonatal brain
(Figures 3 and 4). Despite productive effort in characterizing AAV9’s
receptor binding domain,20 its capsid feature contributing to crossing
the BBB from vasculature remains unknown, although transcytosis
across the endothelial cells of brain blood vessel is a plausible candi-
date mechanism.28,29 We speculate that the AAV9wt and/or
AAV9.HR may employ different routes to cross the BBB in adult
brain and in neonatal brain, which may also reﬂect potential age-
dependent features of the BBB.
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In summary, we demonstrate the feasibility of a combinatory
approach to rAAV capsid development, employing WT AAV capsid
discovery from nature and rational engineering guided by sequence
and structural analysis. A handful of naturally occurring serotype
capsids found in human and NHP lay the foundation of rAAV-
mediated gene therapy,2 some of which are becoming the vectors of
choice for different in vivo gene transfer applications nowadays. In
the future, designing AAV capsids with clinically desired properties
will be a continuing stream of effort. There exists a large repertoire
of AAV capsid in nature, which can be captured in a high-throughput
manner.30 These capsid sequences survive in vivo natural evolution31
and likely possess important features relevant to therapeutic vector
development, such as being able to encapsidate DNA and tissue
tropism. Therefore, these capsids can serve as lead candidates for
further engineering. A better understanding of the capsid sequence,
structure, and function allows for selecting a manageable subset of
natural variants for biological characterization based on computa-
tional predictions, which will accelerate the development of AAV
vectors against a myriad of clinical targets.
MATERIALS AND METHODS
Animal Use
Snap-frozen post mortem tissues from a chimpanzee were obtained
from the University of Louisiana at Lafayette New Iberia Research
Center tissue bank, including brain, liver, lung, and spleen. This
animal died from unrelated health issues and underwent necropsy.
All mice were bred in house and maintained on a 12-hr light cycle.
Only male C57BL/6 WT mice were used due to differences in trans-
duction between genders.32 For IV delivery, 6-week-old mice were
injected with rAAV through tail vein, whereas P1 pups were injected
through facial vein. For IM delivery, 6-week-old mice were injected
at the left tibialis anterior muscle. All injections were performed
using 28.5-gauge needles. The CD mice were described previously.33
Brieﬂy, the Aspa gene is disrupted by a targeted insertion of neo gene
in exon 4. All animal procedures were approved by the Institutional
Animal Care and Use Committee (IACUC) and the Institutional
Biosafety Committee (IBC) at the University of Massachusetts
Medical School.
Isolating AAV Capsid Variants from Chimpanzee Tissues
The chimpanzee tissues were manually ground into powder in liquid
nitrogen using mortar and pestle. Total DNAwas extracted from each
tissue using the QIAamp DNA Mini Kit (QIAGEN; cat no. 51306).
Total RNA was extracted using the TRIzol Reagent (Thermo Fisher
Scientiﬁc; cat no. 15596018), followed by reverse transcription into
cDNA using the High-Capacity cDNA Reverse Transcription Kit
(Thermo Fisher Scientiﬁc; cat no. 4368814). Both DNA and cDNA
samples were used as templates to perform AAV cap gene PCR using
the Platinum PCR SuperMix High Fidelity kit (Thermo Fisher
Scientiﬁc; cat no. 12532016). The primers bind to conserved
sequences found in AAV genome. The forward primer is as follows:
50-GCCGACAGGTACCAAAACAAATGT-30. The reverse primer
is as follows: 50-GAAACGAATTAACCGGTTTATTGATTAA-30.
This PCR yielded products of approximately 2.5 kb pairs (kb)
covering the entire cap gene. After being resolved on agarose gel,
PCR product of the expected size was excised and puriﬁed using
the QIAquick Gel Extraction Kit (QIAGEN; cat no. 28706) and sub-
jected to TOPO cloning using the pCR4-TOPO Vector (Thermo
Fisher Scientiﬁc; cat no. K457502). Plasmid in single colonies of bac-
teria cells was expanded and sequenced by Sanger method. The result-
ing DNA sequence was “translated” into amino acid sequences, which
were aligned with the capsid protein sequences of AAV serotypes 1,
3B, 4, 5, 6, and 9. One of the resulting variants is named as CLv-D8
(chimpanzee liver, clone D8), which is the focus of this study.
Plasmid Constructs and rAAV Vector Production
The ﬁreﬂy luciferase (Fluc)-expressing construct contains a cytomeg-
alovirus enhancer fused with chicken b-actin promoter (CMV/CB)
driving the Fluc gene. The EGFP-expressing construct contains
CMV/CB driving the EGFP gene. Plasmids expressing mutated
CLv-D8 capsid were generated by mutating the isolated CLv-D8
cap gene using the QuikChange II Site-Directed Mutagenesis Kit
(Agilent; cat no. 200523). The construct expressing human ASPA
contains CMV/CB driving a codon-optimized human ASPA cDNA.
The Kozak sequence (GCCACC) is added upstream of the start codon
sequence to enhance gene expression. The Fluc- and ASPA-express-
ing constructs were packaged as single-stranded vectors. The EGFP-
expressing construct was packaged as a sc vector. rAAV vectors were
packaged using a standard triple-transfection protocol as previously
described34 and puriﬁed by CsCl sedimentation. Vector titer was
determined by qPCR for genome titer and gel electrophoresis
followed by silver staining for capsid titer.
In Vivo Imaging
D-luciferin (Gold Biotechnology; cat no. LUCK-1G) was dissolved in
sterile PBS, and aliquots were stored under 80C until use. Mice
were anesthetized by isoﬂurane throughout the procedure. 250 mL
D-luciferin solution was injected into each animal by intraperitoneal
injection. Ten minutes later, luminescence was measured using
the Xenogen IVIS 100 in vivo imaging system in the unit of
photons/s/cm2/sr (PerkinElmer, Waltham, MA).
Structural Modeling of the CLv-D8 Capsid Variant
The 3Dmodel of CLv-D8 was generated in the Coot program35 by us-
ing the “simple mutation” function to introduce amino acid changes
onto the WT AAV9 VP3 monomer (PDB accession number 3UX1).
The four residues that differ between CLv-D8 and AAV9, amino acid
positions 445, 527, 533, and 647, were mutated from tyrosine to
histidine, histidine to tyrosine, arginine to serine, and isoleucine to
threonine, respectively. The side chain orientations of these altered
residues were adjusted to ﬁt structurally allowed rotamers and also
to avoid steric hindrance when necessary. The model was not energy
minimized. The coordinate of the VP3 trimer was generated for the
CLv-D8 model and WT AAV9 crystal structure using the online
VIPERdb server by icosahedral matrix multiplication.36 The CLv-
D8 model was compared to the WT AAV9 structure, and potential
losses/gains of interactions due to the residue mutations were
analyzed interactively in the Coot program.35 The images of the
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variant VP monomer and trimer ribbon representations were gener-
ated using PyMOL program.37
qPCR Assay to Determine rAAV GC Biodistribution
Mice were sacriﬁced by CO2 inhalation followed by cervical disloca-
tion. Tissues of interest were immediately dissected, ﬂash-frozen in
liquid nitrogen, and stored under80C. Frozen tissues were ground
in liquid nitrogen using mortar and pestle. Total DNA was extracted
from an aliquot of tissue powder using the QIAamp DNA Mini Kit
(QIAGEN; cat no. 51306), and DNA concentration was quantiﬁed
by UV spectrometry using a Synergy HT microplate reader (BioTek,
Winooski, VT). 100 ng of total DNAwas used in a qPCR assay using a
Taqman reagent targeting the rabbit b-globin polyadenylation signal
(RBGpA) present in the rAAV genome. The rAAV GC number in
tissue DNA was calculated by comparing against a standard curve
generated using a known amount of plasmid DNA containing the
RBGpA sequence and presented as GC per mouse diploid genome,
assuming that 100 ng of mouse genomic DNA is equivalent to
3  104 mouse haploid genomes.
Luciferase Activity Assay in Tissue Lysate
An aliquot of tissue powder was resuspended in Passive Lysis Buffer
(Promega; cat no. E1941) and underwent three times of freezing in a
dry ice/ethanol bath and thawing in a 37Cwater bath. This method is
efﬁcient in breaking cell membranes and extracting total protein.38
Cell debris was spun down, and clear cell lysate was transferred
into a microcentrifuge tube and kept on ice. Protein concentration
was determined using the Pierce BCA Protein Assay Kit (Thermo
Fisher Scientiﬁc; cat no. 23335). Luciferase activity was determined
using the Luciferase Assay System (Promega; cat no. E1501).
Luciferase activity was calculated as relative light units per 100 mg
of total protein (RLU/100 mg protein).
Blood Clearance of rAAVs
Five microliters of blood was drawn from the tail vein at each time
point as indicated and mixed with 995 mL of PBS. Two microliters
of the diluted blood was directly used in a Taqman qPCR assay to
quantify rAAV genome sequence, namely the RBGpA, by comparing
against a standard curve. To generate the standard curve, the rAAV
vectors of the same batch as used for injection were serially diluted
with 0.5% naive mouse blood and included in the same qPCR assay.
EGFP Fluorescence Detection and Quantification in Peripheral
Tissue Sections
Mice were sacriﬁced by perfusion with ice-cold PBS and 4% parafor-
maldehyde (PFA). Whole body was then immersed in 4% PFA. After
overnight post-ﬁxation, peripheral tissues of interest were cryo-pre-
served by being immersed in 10%, 20%, and 30% sucrose overnight
for each gradient and embedded in O.C.T. Compound (Tissue-Tek;
cat no. 4583). Tissues were cut into 8-mm sections using a cryostat
(cross-section for heart and TA muscle; no speciﬁc orientation for
liver) and mounted on a glass slide using the VECTASHIELD
Mounting Medium with DAPI (Vector Laboratories; cat no.
H-1200). EGFP ﬂuorescence was imaged using an inverted
ﬂuorescence microscope (Leica Microsystems). EGFP signal in
captured images was quantiﬁed using the ImageJ software (NIH).
Immunofluorescence in CNS Tissue Sections andQuantification
of Anti-EGFP Signals
After overnight post-ﬁxation as described above, brain and spinal cord
were carefully dissected and immersed in 4% PFA overnight and then
underwent cryo-preservation and embedding in O.C.T. in the same
manner as for peripheral tissues as mentioned above. CNS tissues
were cut into 40-mm coronal sections using a cryostat. Sections were
co-stained using antibodies against EGFP (Thermo Fisher Scientiﬁc;
cat no. A-11122; 1:1,000 diluted) and NeuN (Millipore; cat no.
MAB377; 1:1,000 diluted) and proper ﬂuorophore-labeled secondary
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Figure 7. IV Delivery of rAAV9.HR-ASPA and rAAV9wt-ASPA at P1 to CD
Mice Rescued Body Weight Loss and Behavioral Deficits
(A) Body weight curves plotted against age of untreated WTmice (green), untreated
CD mice (red), and CD mice treated with rAAV9.HR-ASPA (purple) or rAAV9wt-
ASPA (gray). n = 10 mice per group. (B) Motor function performance of untreated
WT mice (green), untreated CD mice (red), and CD mice treated with rAAV9.HR-
ASPA (purple) or rAAV9wt-ASPA (gray) in three behavioral tests, including rotarod
test, inverted screen test, and balance beam test is shown. All tests were performed
with P27mice (n = 6 per group per test). One-way ANOVAwas performed (p < 0.01).
**p < 0.01 and ns, not significant by Tukey’s multiple comparisons test. Data are
presented as mean and SD.
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antibodies derived from goat (Invitrogen). To stain for blood vessels,
DyLight-labeled tomato lectin was used (Vector Laboratories; cat.
no. DL-1178). Stained sections were mounted as described above.
Immunoﬂuorescence signal from entire section was captured using
an upright ﬂuorescence microscope with tilling function enabled
(Leica Microsystems). Signal quantiﬁcation was performed using the
ImageJ software. Brieﬂy, the regions of interest (ROIs), i.e., cortex,
hippocampus, thalamus, spinal cord ventral, and dorsal horns, were
selected, and the mean intensity within each ROI was automatically
calculated by the software. Confocal microscopy (Leica Microsytems)
was employed to capture both anti-EGFP and anti-NeuN signal in
order to demonstrate co-localization.
MRI and MRS
Anesthesia was induced with isoﬂurane andmaintained with 1.5% iso-
ﬂurane using the Surgivet tabletop isoﬂurane vaporizer (Smiths Med-
ical, Waukesha, WI, USA). Vital signs were monitored throughout the
imaging session. Mice were imaged with a 4.7T/40-cm horizontal
magnet (Oxford, UK) equipped with a Biospec Avance Bruker console
(Bruker, Germany). A 1H radiofrequency mouse head coil (Bruker,
Germany; inner diameter of 23 mm) was used for the experiments.
T2-weighted image acquisition was performed using TurboRARE
sequence with TR = 2,200 ms, TE = 36 ms, echo spacing = 12 ms, 8
averages, and rare factor = 8. Voxel PRESS was used for 1H magnetic
resonance spectroscopy data acquisition (point resolved spectroscopy
sequence; repetition time = 2,500 ms; echo time = 16 ms; number of
averages = 512; voxel size = 3 3 3 mm). For proton spectra ﬁtting,
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Figure 8. Quantification of rAAV Genome Copies and
Transgene Expression following IV Delivery to CD
Mice
(A) Genome copy numbers in ctx, hpc, thl, liver, heart, and
tibialis anterior muscle (TA) in CD mice that were treated with
either rAAVwt-ASPA or rAAV.HR-ASPA at 4.0E+11 GC at
P1. Mice were euthanized four weeks after treatment.
Data are presented as genome copies per diploid genome
(GC/diploid genome). **p < 0.01 and ns, not significant by
Student’s t test. (B) ASPA gene expression (cDNA) normal-
ized toGusb expression in the same tissues of the samemice
described in (A) is shown. **p < 0.01 and ns, not significant by
Student’s t test. All data are presented as mean and SD.
the LCModel (version 6.2-2B) was used. This
model analyzed in vivo proton spectrum linearity
combined with in vitro spectra from individual
metabolite solutions39 and generated data as abso-
lute ﬁts (in institutional units) and SD%. SD was
used to assess reliability of the ﬁt. Inclusion criteria
for the spectra were SD < 20% for NAA, creatine,
and inositol.
Behavioral Tests
Overall motor performance was measured using
accelerated rotarod (Roto-Rod Series 8; IITC Life
Science, Woodland Hills, CA) for coordination
function and endurance, balance beam for vestibular function and
ataxia, and inverted screen for grip strength. The inverted
screen and balance beam equipment was built by the University of
Massachusetts Medical School Machine Shop.
Accelerated Rotarod
Mice were trained for two days prior to testing. On the day of testing,
mice were acclimated for one minute on the beam. Each mouse was
evaluated three times. The best value was counted. The acceleration
and timing was set to 4–40 rpm over ﬁve minutes.
Balance Beam
A single test run lasted for up to ﬁve minutes. Brieﬂy, mice were
placed on the balance beam, and the time until drop-off was recorded.
This was repeated three times, and the best value was counted.
Inverted Screen
A grid of 30 cm2 with 25 mm2 holes in horizontal position was used as
initial setup. Mice were placed in the center and left unchallenged to
acclimate for one minute. Next, the grid was brought to an angle of
125 degrees in order to force the mouse to hang upside down. The
time until drop-off was recorded. The maximum duration of a single
test run was ﬁve minutes.
ddPCR
DNA and RNA were extracted from various tissues using the AllPrep
DNA/RNA Mini Kit (QIAGEN; cat. no. 80204). RNA was reverse
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transcribed into cDNA using the High-Capacity cDNA Reverse
Transcription Kit (Thermo Fisher Scientiﬁc; cat no. 4368814).
Taqman-based multiplexing droplet digital PCR (ddPCR) was
performed using a QX200 ddPCR instrument (Bio-Rad). For both vec-
tor genome analysis and transgene expression analysis, a customized
Taqman reagent targeting the codon-optimized human ASPA
cDNA was used (Thermo Fisher Scientiﬁc; Assay ID APNKRZW).
We used the Taqman reagents targetingmouse Tfrc genomic sequence
(Invitrogen; cat. no. 4458367) and mouse Gusb cDNA sequence
(Invitrogen; Assay ID Mm01197698_m1) as reference for vector
genome analysis and transgene expression analysis, respectively.
Statistical Analysis
Two-tailed Student’s t test was used to compare between two groups.
To compare among multiple groups, one-way ANOVA was used
followed by Tukey’s multiple comparisons test. Statistical analysis
was performed using the GraphPad Prism 7 software.
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